ACELYRIN, INC. Common Stock

SLRN.US
Healthcare · Biotechnology
Price N/A
USD · NASDAQ

Company Information

Company Name
ACELYRIN, INC. Common Stock
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US00445A1007
CIK: 0001962918
Currency: USD
Full Time Employees: 83
Phone: 805 456 4393
Fiscal Year End: December
IPO Date: May 04, 2023
Description:

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. As of May 21, 2025, Acelyrin, Inc. operates as a subsidiary of Alumis Inc.

Address:

4149 Liberty Canyon Road, Agoura Hills, CA, United States, 91301

People

Directors & Officers

Name Title Year Born
Ms. Mina Kim J.D. CEO & Director 1974
Dr. Shephard Mpofu M.D. Chief Medical Officer 1967
Mr. Tyler Marciniak Vice President of Investor Relations, Communications & Corporate Operations NA
Mr. K. Amar Murugan J.D. Chief Legal Officer 1976
Ms. Kelly Chow Chief People Officer NA
Mr. Kenneth A. Lock Chief Commercial Officer 1974
Ms. Patricia A. Turney Chief Technical Operations Officer 1967

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 17, 2025 Amar Murugan N/A Sale 3.91K $2.74 $10.72K
Mar 17, 2025 Mina Kim N/A Sale 17.99K $2.74 $49.28K

Financial Highlights

Market Cap: $229.17M
EBITDA: $-270.06M
Book Value: $4.04
Earnings/Share: $-2.69
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -29.82%
ROE (TTM): -51.08%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $-175.46M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 100.95M
Shares Float: 68.45M
% Insiders: 714.80%
% Institutions: 9,197.70%
Short % Float: 3.85%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Gross Profit
subtotal
$0.00
SG&A
adjust
$-66.81M
R&D
adjust
$-238.06M
Other Operating Expense
adjust
$-11.39M
Operating Income
subtotal
$-316.26M
Other / Non-Operating Items
adjust
$68.03M
Net Income
subtotal
$-248.23M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about SLRN.US!